塞栓療法の世界市場(~2030年):製品別(塞栓剤、サポート装置)、処置別(経カテーテル動脈塞栓術(TAE)、肝動脈放射線塞栓術(TARE)/選択的内部放射線療法(SIRT)、肝動脈化学塞栓術(TACE))、疾患別(癌、末梢血管疾患、神経疾患、泌尿器・腎障害、胃腸障害)、エンドユーザー別(病院・クリニック、外来手術センター)

【英語タイトル】Embolotherapy Market Research Report: By Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological and Nephrological Disorders, Gastrointestinal Disorders), End-User (Hospitals and Clinics, Ambulatory Surgical Centers) - Global Industry Analysis and Demand Forecast to 2030

P&S Market Researchが出版した調査資料(PS21NO009)・商品コード:PS21NO009
・発行会社(調査会社):P&S Market Research
・発行日:2021年9月
・ページ数:370
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
5 UserUSD6,400 ⇒換算¥947,200見積依頼/購入/質問フォーム
Enterprise UserUSD8,400 ⇒換算¥1,243,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本市場調査資料では、塞栓療法の世界市場を広く調査・分析し、調査背景、調査手法、エグゼクティブサマリー、イントロダクション、製品別(塞栓剤、サポート装置)分析、処置別(TAE、TARE/SIRT、TACE)分析、疾患別(癌、末梢血管疾患、神経疾患、泌尿器・腎障害、胃腸障害)分析、エンドユーザー別(病院・クリニック、ASC、その他)分析、市場規模・予測、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・調査背景
・調査手法
・エグゼクティブサマリー
・イントロダクション
・塞栓療法の世界市場規模:製品別(塞栓剤、サポート装置)
・塞栓療法の世界市場規模:処置別(TAE、TARE/SIRT、TACE)
・塞栓療法の世界市場規模:疾患別(癌、末梢血管疾患、神経疾患、泌尿器・腎障害、胃腸障害)
・塞栓療法の世界市場規模:エンドユーザー別(病院・クリニック、ASC、その他)
・市場規模・予測
・塞栓療法の世界市場規模:地域別
・競争状況
・企業情報

Market Overview
The global embolotherapy market stood at $3,082.9 million in 2020, and it is expected to grow at a 7.7% CAGR during 2020–2030. The growing patient pool, escalating prevalence of chronic and lifestyle-associated diseases, increasing healthcare expenditure, and improving healthcare infrastructure are some of the major factors driving the growth of the market.

COVID-19 has spread to almost every country, due to which the number of infected patients is rising, which is straining the countries’ healthcare ecosystem and resources. This is mainly on account of the intensifying demand for healthcare facilities, workers, and, most importantly, medical equipment, devices, drugs, and research studies. To deal with the pandemic, significant changes were made to surgical practice around the world. Furthermore, many general guidelines were released to establish case classification criteria in order to differentiate between elective surgeries that can be postponed and urgent procedures that require immediate intervention. This led to the shutting down of most of the surgical departments in hospitals, which led to a reduced use of products associated with embolotherapy. This posed negative impact on the embolotherapy industry.

Embolic Agents Lead Market due to Their Higher Adoption in Interventional Radiology Procedures
Embolic agents dominated the embolotherapy market in 2020, based on product. The increasing use of embolic agents in various interventional radiology procedures is the primary reason for this product category’s dominance on the market. Furthermore, due to the advancements in such agents, such as calibrated microspheres for bland embolization, drug-eluting microspheres, and radioactive yttrium-90 (Y-90) microspheres, for treating primary or secondary liver disease, the category is expected to grow at the higher rate over the forecast period (2021–2030).

TAE To Witness Fastest Growth due to Its Higher Adoption over other Procedures
In the embolotherapy market, transcatheter arterial embolization (TAE) is expected to be the fastest-growing category during the forecast period, based on procedure. This is attributed to the proliferating demand for minimally invasive procedures and rapidly growing geriatric population. Moreover, TAE is effective and well-tolerated in patients with ruptured hepatocellular carcinoma (HCC), and it is preferred over transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/ selective internal radiation therapy (SIRT).

North America Dominated Market due to Its Strong Healthcare Ecosystem
North America dominated the market for embolotherapy in 2020, and it is expected to hold the largest market share during the forecast period as well. The increasing prevalence of indications that require embolization procedures, established healthcare ecosystem, and development of advanced embolic agents by the players operating in the region are some of the major reasons for the growth of the North American market.

Product Approvals and Launches Key Market Trends
Over the past few years, key players in the embolotherapy market have been focusing on the commercialization of new products for embolization. For instance, in December 2020, Terumo Medical Corporation introduced the first intrasaccular flow disruptor device in the Japanese market, under the brand name Woven EndoBridge (WEB) Embolization System, for the treatment of brain aneurysms. Moreover, in September 2019, Merit Medical Systems Inc. launched Torpedo, a proprietary gelatin foam loaded into a cartridge with an optional blunt stylet, for the smooth delivery of Torpedo to the target vasculature via a syringe.

Growing Patient Pool Key Driver for Market
The embolotherapy market is witnessing growth on account of the increase in the number of patients seeking embolization for the treatment of HCC, renal cell carcinoma (RCC), varicose veins, and aneurysms. According to the Centers for Disease Control and Prevention (CDC), in 2018, aortic aneurysms were responsible for 9,923 deaths in the U.S., which shows the unmet medical need for such procedures. Hence, the increasing patient pool strengthens the demand for embolization procedures.

Increasing Prevalence of Chronic and Lifestyle-Associated Diseases also Helping Market Advance
The prolonged exposure to four modifiable lifestyle behaviors, namely smoking, unhealthy diet, alcohol consumption, and physical inactivity, often results in chronic diseases, including stroke, diabetes, obesity, metabolic syndrome, chronic obstructive pulmonary disease, and various types of cancer. Chronic diseases are a major healthcare burden affecting high-income as well as low- and middle-income countries (LMICs). Cancer, hepatitis, and central nervous system disorders are some of the chronic diseases that require advanced treatment. Thus, the increase in the prevalence of chronic and lifestyle-associated diseases is driving the embolotherapy market globally.

❖ レポートの目次 ❖

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Embolic agents
4.1.1.1.1 Microspheres
4.1.1.1.2 Embolic coils
4.1.1.1.3 Liquid embolic agents
4.1.1.1.4 Embolic plug systems
4.1.1.1.5 Detachable balloons
4.1.1.2 Support devices
4.1.1.2.1 Microcatheters
4.1.1.2.2 Guidewires
4.1.2 By Procedure
4.1.2.1 TAE
4.1.2.2 TARE/SIRT
4.1.2.3 TACE
4.1.3 By Indication
4.1.3.1 Cancer
4.1.3.1.1 Kidney
4.1.3.1.2 Liver
4.1.3.1.3 Others
4.1.3.2 Peripheral vascular diseases
4.1.3.3 Neurological diseases
4.1.3.3.1 Cerebral aneurysm
4.1.3.3.2 Arteriovenous malformations & fistulas
4.1.3.4 Urological and nephrological disorders
4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
4.1.4.1 Hospitals & clinics
4.1.4.2 ASCs
4.1.4.3 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.2 Drivers
4.2.2.1 Growing patient pool
4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.3 Growing medical tourism sector
4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.5 Growing preference for MISs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Product recalls
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of liquid embolic agents
4.2.4.2 Untapped market in developing economies
4.3 Porter’s Five Forces Analysis
4.4 Regulatory Framework Analysis
4.4.1 U.S.
4.4.2 Europe
4.4.3 APAC
4.4.4 LATAM
4.4.5 MEA
Chapter 5. Global Market Size and Forecast
5.1 Global Market Size and Forecast
5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
5.3 By Procedure
5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
6.2 By Procedure
6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
6.4 By End User
6.5 By Country
6.5.1 U.S. Market Size and Forecast
6.5.1.1 By product
6.5.1.1.1 Embolic agents market, by type
6.5.1.1.2 Embolotherapy support devices market, by type
6.5.1.2 By procedure
6.5.1.3 By indication
6.5.1.3.1 Embolotherapy market for cancer, by type
6.5.1.3.2 Embolotherapy market for neurological diseases, by type
6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
6.5.2.1 By product
6.5.2.1.1 Embolic agents market, by type
6.5.2.1.2 Embolotherapy support devices market, by type
6.5.2.2 By procedure
6.5.2.3 By indication
6.5.2.3.1 Embolotherapy market for cancer, by type
6.5.2.3.2 Embolotherapy market for neurological diseases, by type
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 Germany Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 France Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
7.5.3.1 By product
7.5.3.1.1 Embolic agents market, by type
7.5.3.1.2 Embolotherapy support devices market, by type
7.5.3.2 By procedure
7.5.3.3 By indication
7.5.3.3.1 Embolotherapy market for cancer, by type
7.5.3.3.2 Embolotherapy market for neurological diseases, by type
7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
7.5.4.1 By product
7.5.4.1.1 Embolic agents market, by type
7.5.4.1.2 Embolotherapy support devices market, by type
7.5.4.2 By procedure
7.5.4.3 By indication
7.5.4.3.1 Embolotherapy market for cancer, by type
7.5.4.3.2 Embolotherapy market for neurological diseases, by type
7.5.4.4 By end user
7.5.5 Spain Market Size and Forecast
7.5.5.1 By product
7.5.5.1.1 Embolic agents market, by type
7.5.5.1.2 Embolotherapy support devices market, by type
7.5.5.2 By procedure
7.5.5.3 By indication
7.5.5.3.1 Embolotherapy market for cancer, by type
7.5.5.3.2 Embolotherapy market for neurological diseases, by type
7.5.5.4 By end user
Chapter 8. APAC Market Size and Forecast
8.1 By Product
8.1.1 Embolic Agents Market, by Type
8.1.2 Embolotherapy Support Devices Market, by Type
8.2 By Procedure
8.3 By Indication
8.3.1 Embolotherapy Market for Cancer, by Type
8.3.2 Embolotherapy Market for Neurological Diseases, by Type
8.4 By End User
8.5 By Country
8.5.1 China Market Size and Forecast
8.5.1.1 By product
8.5.1.1.1 Embolic agents market, by type
8.5.1.1.2 Embolotherapy support devices market, by type
8.5.1.2 By procedure
8.5.1.3 By indication
8.5.1.3.1 Embolotherapy market for cancer, by type
8.5.1.3.2 Embolotherapy market for neurological diseases, by type
8.5.1.4 By end user
8.5.2 Japan Market Size and Forecast
8.5.2.1 By product
8.5.2.1.1 Embolic agents market, by type
8.5.2.1.2 Embolotherapy support devices market, by type
8.5.2.2 By procedure
8.5.2.3 By indication
8.5.2.3.1 Embolotherapy market for cancer, by type
8.5.2.3.2 Embolotherapy market for neurological diseases, by type
8.5.2.4 By end user
8.5.3 India Market Size and Forecast
8.5.3.1 By product
8.5.3.1.1 Embolic agents market, by type
8.5.3.1.2 Embolotherapy support devices market, by type
8.5.3.2 By procedure
8.5.3.3 By indication
8.5.3.3.1 Embolotherapy market for cancer, by type
8.5.3.3.2 Embolotherapy market for neurological diseases, by type
8.5.3.4 By end user
8.5.4 South Korea Market Size and Forecast
8.5.4.1 By product
8.5.4.1.1 Embolic agents market, by type
8.5.4.1.2 Embolotherapy support devices market, by type
8.5.4.2 By procedure
8.5.4.3 By indication
8.5.4.3.1 Embolotherapy market for cancer, by type
8.5.4.3.2 Embolotherapy market for neurological diseases, by type
8.5.4.4 By end user
8.5.5 Singapore Market Size and Forecast
8.5.5.1 By product
8.5.5.1.1 Embolic agents market, by type
8.5.5.1.2 Embolotherapy support devices market, by type
8.5.5.2 By procedure
8.5.5.3 By indication
8.5.5.3.1 Embolotherapy market for cancer, by type
8.5.5.3.2 Embolotherapy market for neurological diseases, by type
8.5.5.4 By end user
Chapter 9. LATAM Market Size and Forecast
9.1 By Product
9.1.1 Embolic Agents Market, by Type
9.1.2 Embolotherapy Support Devices Market, by Type
9.2 By Procedure
9.3 By Indication
9.3.1 Embolotherapy Market for Cancer, by Type
9.3.2 Embolotherapy Market for Neurological Diseases, by Type
9.4 By End User
9.5 By Country
9.5.1 Brazil Market Size and Forecast
9.5.1.1 By product
9.5.1.1.1 Embolic agents market, by type
9.5.1.1.2 Embolotherapy support devices market, by type
9.5.1.2 By procedure
9.5.1.3 By indication
9.5.1.3.1 Embolotherapy market for cancer, by type
9.5.1.3.2 Embolotherapy market for neurological diseases, by type
9.5.1.4 By end user
9.5.2 Mexico Market Size and Forecast
9.5.2.1 By product
9.5.2.1.1 Embolic agents market, by type
9.5.2.1.2 Embolotherapy support devices market, by type
9.5.2.2 By procedure
9.5.2.3 By indication
9.5.2.3.1 Embolotherapy market for cancer, by type
9.5.2.3.2 Embolotherapy market for neurological diseases, by type
9.5.2.4 By end user
Chapter 10. MEA Market Size and Forecast
10.1 By Product
10.1.1 Embolic Agents Market, by Type
10.1.2 Embolotherapy Support Devices Market, by Type
10.2 By Procedure
10.3 By Indication
10.3.1 Embolotherapy Market for Cancer, by Type
10.3.2 Embolotherapy Market for Neurological Diseases, by Type
10.4 By End User
10.5 By Country
10.5.1 Saudi Arabia Market Size and Forecast
10.5.1.1 By product
10.5.1.1.1 Embolic agents market, by type
10.5.1.1.2 Embolotherapy support devices market, by type
10.5.1.2 By procedure
10.5.1.3 By indication
10.5.1.3.1 Embolotherapy market for cancer, by type
10.5.1.3.2 Embolotherapy market for neurological diseases, by type
10.5.1.4 By end user
10.5.2 South Africa Market Size and Forecast
10.5.2.1 By product
10.5.2.1.1 Embolic agents market, by type
10.5.2.1.2 Embolotherapy support devices market, by type
10.5.2.2 By procedure
10.5.2.3 By indication
10.5.2.3.1 Embolotherapy market for cancer, by type
10.5.2.3.2 Embolotherapy market for neurological diseases, by type
10.5.2.4 By end user
Chapter 11. Competitive Landscape
11.1 List of Other Players
11.2 Strategic Developments of Key Players
11.2.1 Product Launches & Approvals
11.2.2 Collaborations
11.2.3 Acquisitions
11.2.4 Expansions
Chapter 12. Company Profiles
12.1 Stryker Corporation
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2 Sirtex Medical Limited
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.3 Key Financial Summary
12.3 Merit Medical Systems Inc.
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Meril Life Sciences Pvt. Ltd.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.5 Acandis GmbH
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.6 Terumo Corporation
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Medtronic plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Kaneka Corporation
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 Johnson & Johnson
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
12.10 Boston Scientific Corporation
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
12.11 Abbott Laboratories
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
12.12 Guerbet
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
12.13 BALT EXTRUSION SAS
12.13.1 Business Overview
12.13.2 Product and Service Offerings
Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports



★調査レポート[塞栓療法の世界市場(~2030年):製品別(塞栓剤、サポート装置)、処置別(経カテーテル動脈塞栓術(TAE)、肝動脈放射線塞栓術(TARE)/選択的内部放射線療法(SIRT)、肝動脈化学塞栓術(TACE))、疾患別(癌、末梢血管疾患、神経疾患、泌尿器・腎障害、胃腸障害)、エンドユーザー別(病院・クリニック、外来手術センター)] (コード:PS21NO009)販売に関する免責事項を必ずご確認ください。
★調査レポート[塞栓療法の世界市場(~2030年):製品別(塞栓剤、サポート装置)、処置別(経カテーテル動脈塞栓術(TAE)、肝動脈放射線塞栓術(TARE)/選択的内部放射線療法(SIRT)、肝動脈化学塞栓術(TACE))、疾患別(癌、末梢血管疾患、神経疾患、泌尿器・腎障害、胃腸障害)、エンドユーザー別(病院・クリニック、外来手術センター)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆